Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation

Table 1 ADV monotherapy vs ADV/LAM combination therapy in patients with lamivudine-resistant chronic hepatitis B

Ref.	Patients (n)		Undetectable HBV DNA		Follow up	P	Normalization of ALT		Follow up	P	ADV resistance		Follow-up	P
	A	AL	A (%)	AL (%)			A (%)	AL (%)			A (%)	AL (%)
[36]	14	28	79	89	At month 36	0.26	73	91	At month 24	0.69	21	0	At month 36	0.020
[37]	23	36	82	89	At month 24	> 0.50	53	79	At month 24	> 0.50	22	0	At month 24	0.001
[38]	28	28	64	40	At month 24	0.38	80	74	At month 12	0.72	18	7	At month 24	0.940
[39]	34	36	82	97	At month 12	> 0.50	79	96	At month 12	> 0.50	18	3	At month 12	> 0.500

A: ADV monotherapy; AL: ADV/LAM combination therapy.